Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

Authors: Sin-Hee Park, Muhammad Akmal Farooq, Sébastien Gaertner, Christophe Bruckert, Abdul Wahid Qureshi, Hyun-Ho Lee, Djamel Benrahla, Brigitte Pollet, Dominique Stephan, Patrick Ohlmann, Jean-Marc Lessinger, Eric Mayoux, Cyril Auger, Olivier Morel, Valérie B. Schini-Kerth

Source: Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-14 (2020)

Subject Terms: Empagliflozin, SGLT2, Endothelial function, Heart function, Heart structure, Senescence, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s12933-020-00997-7; https://doaj.org/toc/1475-2840

Access URL: https://doaj.org/article/1a781d74075649d3919486e0c679b5b4

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans

Authors: Heeyoung Chae, Robert Augustin, Eva Gatineau, Eric Mayoux, Mohammed Bensellam, Nancy Antoine, Firas Khattab, Bao-Khanh Lai, Davide Brusa, Birgit Stierstorfer, Holger Klein, Bilal Singh, Lucie Ruiz, Michael Pieper, Michael Mark, Pedro L. Herrera, Fiona M. Gribble, Frank Reimann, Anne Wojtusciszyn, Christophe Broca, Nano Rita, Lorenzo Piemonti, Patrick Gilon

Source: Molecular Metabolism, Vol 42, Iss , Pp 101071- (2020)

Subject Terms: Gliflozins, SGLT2 inhibitor, Glucagon, Insulin, Diabetes, Internal medicine, RC31-1245

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2212877820301459; https://doaj.org/toc/2212-8778

Access URL: https://doaj.org/article/21bfada24dc04976b5da4c463b456525

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

Authors: Annayya R. Aroor, Nitin A. Das, Andrea J. Carpenter, Javad Habibi, Guanghong Jia, Francisco I. Ramirez-Perez, Luis Martinez-Lemus, Camila M. Manrique-Acevedo, Melvin R. Hayden, Cornel Duta, Ravi Nistala, Eric Mayoux, Jaume Padilla, Bysani Chandrasekar, Vincent G. DeMarco

Source: Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-14 (2018)

Subject Terms: Vascular stiffness, Renal resistivity, SGLT2, RECK, Pulsatility index, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s12933-018-0750-8; https://doaj.org/toc/1475-2840

Access URL: https://doaj.org/article/762775bbe4d347228d8b8580356663b2

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

Authors: Sebastian Steven, Matthias Oelze, Alina Hanf, Swenja Kröller-Schön, Fatemeh Kashani, Siyer Roohani, Philipp Welschof, Maximilian Kopp, Ute Gödtel-Armbrust, Ning Xia, Huige Li, Eberhard Schulz, Karl J. Lackner, Leszek Wojnowski, Serge P. Bottari, Philip Wenzel, Eric Mayoux, Thomas Münzel, Andreas Daiber

Source: Redox Biology, Vol 13, Iss C, Pp 370-385 (2017)

Subject Terms: SGLT2 inhibitor, Zucker diabetic fatty rats, Diabetes, Oxidative stress, Endothelial dysfunction, Low-grade inflammation, AGE/RAGE signaling, β-cell content, Medicine (General), R5-920, Biology (General), QH301-705.5

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2213231717303932; https://doaj.org/toc/2213-2317

Access URL: https://doaj.org/article/7e8a8df60a79492ab7f5ea227c2d7c8b

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

Authors: Liang Xu, Naoto Nagata, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Guanliang Chen, Eric Mayoux, Shuichi Kaneko, Tsuguhito Ota

Source: EBioMedicine, Vol 20, Iss C, Pp 137-149 (2017)

Subject Terms: Sodium glucose cotransporter-2 inhibitor, Obesity, Energy metabolism, Brown adipose tissue, Inflammation, Macrophage, Medicine, Medicine (General), R5-920

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2352396417302268; https://doaj.org/toc/2352-3964

Access URL: https://doaj.org/article/ec13e591e3f244278f0b38479ba3d610

The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.

Authors: Sam Tsz Wai Cheng, Lihua Chen, Stephen Yu Ting Li, Eric Mayoux, Po Sing Leung

Source: PLoS ONE, Vol 11, Iss 1, p e0147391 (2016)

Subject Terms: Medicine, Science

File Description: electronic resource

Relation: http://europepmc.org/articles/PMC4726656?pdf=render; https://doaj.org/toc/1932-6203

Access URL: https://doaj.org/article/32ea288b86ed4cb2989b7cc7a58f665c

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.

Authors: Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mader, Elena Zinßius, Saule Agdauletova, Anna Gottschlich, Sebastian Steven, Eberhard Schulz, Serge P Bottari, Eric Mayoux, Thomas Münzel, Andreas Daiber

Source: PLoS ONE, Vol 9, Iss 11, p e112394 (2014)

Subject Terms: Medicine, Science

File Description: electronic resource

Relation: http://europepmc.org/articles/PMC4234367?pdf=render; https://doaj.org/toc/1932-6203

Access URL: https://doaj.org/article/89298fb08472410b8081d15236c79a94

This result is not displayed to guests.
Login for full access.